Merontos, Menzl Mae V.

HRN: 13 21 16  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/30/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/30/2023
06/06/2023
IV
500mg
Q6hrs
Intestinal Amoebiasis
Waiting Final Action 

Indication:  Empirical Escalation    Type of Infection:  Intra-abdominalFebrile Neutropenia    Compliance to guidelines: Guideline Not Available

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: